BioSpace News Archive

Homology Medicines, Inc., a genetic medicines company, announced enrollment and site status updates from the pheEDIT Phase 1 gene editing trial with HMI-103 for phenylketonuria and the juMPStart Phase 1 gene therapy trial with HMI-203 for Hunter syndrome.

Precigen, Inc. announced that the Company will host an investigator-led R&D event on January 24, 2023 at 4:30 PM ET to showcase the latest clinical advancements for the Company’s investigational, first-in-class PRGN-2012 off-the-shelf AdenoVerse™ Immunotherapy in recurrent respiratory papillomatosis.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time at The Westin St. Francis in San Francisco, CA.

Personalis, Inc., a leader in advanced genomics for precision oncology, reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2022.

Orthofix Medical Inc. and SeaSpine Holdings Corporation announced the successful completion of their previously announced merger of equals following the approval of each company’s stockholders at respective special meetings of stockholders.

SOPHiA GENETICS SA announced that Dr. Jurgi Camblong, Chief Executive Officer and Co-Founder, is scheduled to present at the J.P. Morgan 2023 Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. PST in San Francisco.

Vyant Bio, Inc. is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Celularity Inc., a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2, 2023.

Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a precision cardiovascular diagnostics company, announced today that it will attend the JP Morgan Healthcare Conference, January 9-12, 2023.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced that the Company’s board of directors has approved a 1-for-20 reverse stock split of its shares of common stock.